NCT07270120
Senolytics for Secondary Progressive MS
Not Yet Recruiting · Phase 1 · Ohio State University · registry updated 2025-12-08
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
This is a clinical trial to see whether senolytic therapy is safe and feasible for patients with secondary progressive MS and whether treatment improves physical and thinking abilities. The study seeks to enroll adults with secondary progressive MS (SPMS), aged 50-85, who are not currently taking a MS disease-modifying therapy and have noticed their MS symptoms getting worse. People who join the study will take the medicines dasatinib and quercetin by mouth every two weeks for three months. These medicines work together to remove old, damaged cells that may cause inflammation and slow the repair of nerves. Participants will also be followed for one year from enrollment to monitor for treatment effects.
Inclusion
- Individuals aged 50-85 with SPMS diagnosed using the 2024 McDonald Criteria
- Not treated with a DMT for MS within the last 6 months or have used alemtuzumab, cladribine, or mitoxantrone.
- Evidence of MS progression over the past 12 months.
Exclusion
- Unstable coronary artery disease (myocardial infarction within 6 months or angina)
- Hospitalization within 6 months
- Stroke or transient ischemic attack in the past 6 months
- Pulmonary arterial hypertension
- Current or chronic history of liver disease
- Alzheimer's or Parkinson's disease